Viemed Healthcare (VMD) Financials

$6.56 -0.01 (-0.15%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$6.65 +0.09 (+1.37%)

As of 05/30/2025 04:04 PM Eastern

Annual Income Statements for Viemed Healthcare

This table shows Viemed Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	11	10	6.22
Consolidated Net Income / (Loss)	11	10	6.22
Net Income / (Loss) Continuing Operations	11	10	6.22
Total Pre-Tax Income	16	14	8.99
Total Operating Income	18	14	8.25
Total Gross Profit	133	113	85
Total Revenue	224	183	139
Operating Revenue	224	183	139
Total Cost of Revenue	91	70	54
Operating Cost of Revenue	91	70	54
Total Operating Expenses	117	99	77
Selling, General & Admin Expense	106	88	68
Research & Development Expense	3.07	2.78	2.70
Depreciation Expense	1.48	1.39	1.01
Other Operating Expenses / (Income)	6.29	5.85	5.20
Total Other Income / (Expense), net	0.00	0.16	1.73
Interest & Investment Income	-1.73	0.06	0.74
Other Income / (Expense), net	1.73	0.10	0.99
Income Tax Expense	4.76	4.15	2.77
Net Income / (Loss) Attributable to Noncontrolling Interest	0.14	0.00	0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.00	-	-
Basic Earnings per Share	$0.29	$0.27	$0.16
Weighted Average Basic Shares Outstanding	38.75M	38.35M	38.66M
Diluted Earnings per Share	$0.28	$0.25	$0.16
Weighted Average Diluted Shares Outstanding	40.81M	40.38M	39.81M
Weighted Average Basic & Diluted Shares Outstanding	39.52M	38.76M	38.17M

This table shows Viemed Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	4.32	3.88	1.47	1.60	3.48	2.92	2.33	1.52	2.33	1.17
Consolidated Net Income / (Loss)	4.42	3.91	1.48	1.60	3.48	2.92	2.33	1.52	2.44	1.06
Net Income / (Loss) Continuing Operations	4.42	3.91	1.48	1.60	3.48	2.92	2.33	1.52	2.44	1.06
Total Pre-Tax Income	6.31	5.50	2.25	2.12	5.08	4.24	3.06	2.02	3.58	1.51
Total Operating Income	6.45	5.63	3.62	2.20	5.29	4.21	2.90	1.93	3.53	1.47
Total Gross Profit	36	34	33	30	32	31	26	24	23	22
Total Revenue	61	58	55	51	51	49	43	40	38	36
Operating Revenue	61	58	55	51	51	49	43	40	38	36
Total Cost of Revenue	25	24	22	21	19	19	17	16	15	14
Operating Cost of Revenue	25	24	22	21	19	19	17	16	15	14
Total Operating Expenses	32	29	29	28	27	26	23	22	20	20
Selling, General & Admin Expense	28	27	27	25	24	24	21	20	17	18
Research & Development Expense	0.80	0.76	0.76	0.75	0.65	0.59	0.76	0.78	0.72	0.67
Depreciation Expense	0.34	0.35	0.38	0.42	0.43	0.42	0.30	0.24	0.24	0.29
Other Operating Expenses / (Income)	1.52	1.71	1.62	1.43	1.53	1.45	1.47	1.39	1.98	1.31
Total Other Income / (Expense), net	1.85	0.15	-1.93	-0.06	-0.24	0.07	0.16	0.17	0.98	0.10
Interest & Investment Income	-0.15	-0.13	-1.37	-0.08	-0.21	0.03	0.16	0.08	0.05	0.04
Other Income / (Expense), net	1.99	0.28	-0.56	0.03	-0.03	0.04	0.00	0.08	-	0.06
Income Tax Expense	1.88	1.59	0.77	0.52	1.60	1.32	0.73	0.50	1.15	0.46
Basic Earnings per Share	$0.11	$0.10	$0.04	$0.04	$0.09	$0.08	$0.06	$0.04	$0.07	$0.03
Weighted Average Basic Shares Outstanding	38.75M	38.87M	38.82M	38.72M	38.35M	38.44M	38.32M	38.16M	38.66M	38.23M
Diluted Earnings per Share	$0.10	$0.10	$0.04	$0.04	$0.08	$0.07	$0.06	$0.04	$0.07	$0.03
Weighted Average Diluted Shares Outstanding	40.81M	40.78M	40.55M	40.58M	40.38M	40.42M	40.68M	40.02M	39.81M	39.58M
Weighted Average Basic & Diluted Shares Outstanding	39.52M	38.94M	38.83M	38.82M	38.76M	38.49M	38.40M	38.28M	38.17M	38.02M

This table details how cash moves in and out of Viemed Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	4.70	-4.08	-11
Net Cash From Operating Activities	39	45	28
Net Cash From Continuing Operating Activities	39	45	28
Net Income / (Loss) Continuing Operations	11	10	6.22
Consolidated Net Income / (Loss)	11	10	6.22
Depreciation Expense	25	22	16
Amortization Expense	0.19	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	5.61	6.77	4.27
Changes in Operating Assets and Liabilities, net	-3.49	6.34	1.62
Net Cash From Investing Activities	-31	-52	-24
Net Cash From Continuing Investing Activities	-31	-52	-24
Purchase of Property, Plant & Equipment	-39	-26	-23
Acquisitions	-3.00	-29	0.00
Purchase of Investments	0.00	0.00	-2.00
Sale of Property, Plant & Equipment	10	2.59	1.06
Sale and/or Maturity of Investments	0.75	0.00	0.00
Net Cash From Financing Activities	-3.69	2.83	-15
Net Cash From Continuing Financing Activities	-3.69	2.83	-15
Repayment of Debt	-6.60	-11	-5.80
Repurchase of Common Equity	0.00	0.00	-9.57
Payment of Dividends	-0.04	0.00	0.00
Issuance of Debt	3.00	13	0.00
Other Financing Activities, net	-0.05	0.55	0.10
Cash Interest Paid	0.95	0.85	0.23
Cash Income Taxes Paid	6.83	3.57	-0.85

This table details how cash moves in and out of Viemed Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	6.19	2.54	1.50	-5.53	2.76	-0.15	-13	6.63	-4.56	-0.44
Net Cash From Operating Activities	15	13	10	1.18	13	14	7.62	10	7.68	7.97
Net Cash From Continuing Operating Activities	15	13	10	1.18	13	14	7.62	10	7.68	7.97
Net Income / (Loss) Continuing Operations	4.42	3.91	1.48	1.60	3.48	2.92	2.33	1.52	2.44	1.06
Consolidated Net Income / (Loss)	4.42	3.91	1.48	1.60	3.48	2.92	2.33	1.52	2.44	1.06
Depreciation Expense	6.37	6.41	6.31	6.29	5.92	5.98	5.21	4.76	4.37	4.12
Amortization Expense	0.05	0.05	-	-	-	-	-	-	-	-
Non-Cash Adjustments To Reconcile Net Income	0.42	1.37	2.25	1.57	1.86	1.85	1.59	1.47	1.56	1.84
Changes in Operating Assets and Liabilities, net	3.73	1.01	0.06	-8.29	2.03	3.07	-1.51	2.74	-0.69	0.96
Net Cash From Investing Activities	-9.20	-4.97	-11	-5.37	-7.49	-8.51	-32	-3.91	-7.38	-6.10
Net Cash From Continuing Investing Activities	-9.20	-4.97	-11	-5.37	-7.49	-8.51	-32	-3.91	-7.38	-6.10
Purchase of Property, Plant & Equipment	-13	-11	-8.93	-6.01	-7.95	-7.40	-6.09	-4.68	-5.57	-6.36
Sale of Property, Plant & Equipment	2.88	6.03	0.77	0.64	0.46	0.35	1.00	0.78	0.19	0.25
Net Cash From Financing Activities	0.40	-5.24	2.48	-1.34	-3.03	-5.45	11	0.04	-4.87	-2.31
Net Cash From Continuing Financing Activities	0.40	-5.24	2.48	-1.34	-3.03	-5.45	11	0.04	-4.87	-2.31
Repayment of Debt	-0.16	-5.23	-0.62	-0.59	-2.94	-5.42	-2.36	0.00	-4.36	-0.48
Other Financing Activities, net	0.60	-0.00	0.10	-0.75	-0.09	-0.03	0.63	0.04	0.20	0.02
Cash Interest Paid	0.21	0.23	0.29	0.22	0.35	0.33	0.13	0.04	0.05	0.06
Cash Income Taxes Paid	0.41	2.58	3.84	0.00	0.35	0.13	3.13	-0.04	0.07	0.02

This table presents Viemed Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	177	155	117
Total Current Assets	53	38	40
Cash & Equivalents	18	13	17
Accounts Receivable	25	18	15
Inventories, net	4.32	4.63	3.57
Prepaid Expenses	6.11	2.45	3.85
Plant, Property, & Equipment, net	76	74	68
Total Noncurrent Assets	48	43	9.56
Long-Term Investments	2.79	1.68	-
Noncurrent Note & Lease Receivables	0.05	0.40	0.00
Goodwill	33	30	0.00
Intangible Assets	0.85	0.57	0.00
Noncurrent Deferred & Refundable Income Taxes	8.40	4.56	3.12
Other Noncurrent Operating Assets	2.83	5.98	6.44
Total Liabilities & Shareholders' Equity	177	155	117
Total Liabilities	44	41	20
Total Current Liabilities	37	32	19
Short-Term Debt	0.41	1.07	0.00
Accounts Payable	5.32	4.18	2.65
Accrued Expenses	20	18	11
Current Deferred Revenue	6.69	6.21	4.62
Current Deferred & Payable Income Tax Liabilities	3.88	2.15	0.00
Other Current Liabilities	0.86	0.93	0.50
Total Noncurrent Liabilities	6.44	8.88	1.09
Long-Term Debt	3.59	6.00	0.00
Other Noncurrent Operating Liabilities	2.85	2.87	1.09
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	133	114	97
Total Preferred & Common Equity	131	114	97
Total Common Equity	131	114	97
Common Stock	42	34	27
Retained Earnings	90	79	70
Noncontrolling Interest	1.91	0.00	-

This table presents Viemed Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	170	164	155	149	149	125	119
Total Current Assets	48	45	39	36	36	47	43
Cash & Equivalents	11	8.81	7.31	10	10	24	21
Short-Term Investments	1.79	1.79	-	-	-	1.99	2.22
Accounts Receivable	27	27	24	18	18	16	15
Inventories, net	4.31	4.42	4.35	4.67	4.48	3.45	3.18
Prepaid Expenses	4.99	4.24	2.48	3.19	2.33	3.39	3.14
Plant, Property, & Equipment, net	74	75	74	73	73	68	68
Total Noncurrent Assets	45	41	43	40	40	5.44	6.23
Noncurrent Note & Lease Receivables	0.07	0.13	0.30	0.53	0.54	-	-
Goodwill	33	33	30	30	30	-	-
Intangible Assets	0.88	0.91	0.53	0.69	0.69	-	-
Noncurrent Deferred & Refundable Income Taxes	8.07	4.56	4.56	3.91	3.84	3.84	3.93
Other Noncurrent Operating Assets	2.76	2.89	7.59	5.28	5.46	1.60	2.30
Total Liabilities & Shareholders' Equity	170	164	155	149	149	125	119
Total Liabilities	43	43	39	41	45	25	26
Total Current Liabilities	36	31	30	32	32	23	21
Short-Term Debt	0.81	0.77	0.60	1.83	3.17	-	0.17
Accounts Payable	6.01	6.33	5.80	5.98	6.17	4.26	3.74
Accrued Expenses	20	17	14	17	16	13	12
Current Deferred Revenue	6.82	6.72	6.09	6.22	5.96	4.70	4.65
Current Deferred & Payable Income Tax Liabilities	2.08	0.00	2.68	0.23	-	1.25	-
Other Current Liabilities	0.81	0.85	0.90	0.58	0.77	0.40	-
Total Noncurrent Liabilities	6.29	11	8.49	9.03	13	1.17	4.95
Long-Term Debt	3.65	8.72	5.91	8.10	12	-	4.16
Other Noncurrent Operating Liabilities	2.64	2.57	2.58	0.94	0.92	1.17	0.56
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	127	121	116	109	105	100	94
Total Preferred & Common Equity	125	119	116	109	105	100	94
Total Common Equity	125	119	116	109	105	100	94
Common Stock	40	38	36	33	31	29	26
Retained Earnings	85	82	80	76	73	71	68
Noncontrolling Interest	1.84	1.81	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Viemed Healthcare's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	22.54%	31.82%	18.60%
EBITDA Growth	24.52%	45.91%	8.64%
EBIT Growth	36.07%	56.13%	-20.20%
NOPAT Growth	23.83%	78.59%	-32.43%
Net Income Growth	11.38%	64.63%	-31.82%
EPS Growth	12.00%	56.25%	-27.27%
Operating Cash Flow Growth	-13.54%	62.94%	23.36%
Free Cash Flow Firm Growth	113.16%	-607.71%	57.96%
Invested Capital Growth	9.88%	32.76%	11.06%
Revenue Q/Q Growth	4.65%	7.79%	4.16%
EBITDA Q/Q Growth	9.22%	10.33%	4.68%
EBIT Q/Q Growth	19.34%	14.74%	-1.51%
NOPAT Q/Q Growth	7.77%	13.67%	-19.10%
Net Income Q/Q Growth	9.05%	11.29%	-20.95%
EPS Q/Q Growth	7.69%	4.17%	-15.79%
Operating Cash Flow Q/Q Growth	4.56%	14.14%	-3.38%
Free Cash Flow Firm Q/Q Growth	-32.73%	34.95%	-372.31%
Invested Capital Q/Q Growth	-0.24%	-2.04%	6.92%
Profitability Metrics	-	-	-
Gross Margin	59.40%	61.63%	60.99%
EBITDA Margin	20.15%	19.83%	17.91%
Operating Margin	7.98%	7.83%	5.94%
EBIT Margin	8.75%	7.88%	6.66%
Profit (Net Income) Margin	5.09%	5.60%	4.48%
Tax Burden Percent	70.56%	71.18%	69.21%
Interest Burden Percent	82.37%	99.74%	97.28%
Effective Tax Rate	29.44%	28.82%	30.79%
Return on Invested Capital (ROIC)	11.31%	10.93%	7.50%
ROIC Less NNEP Spread (ROIC-NNEP)	21.57%	10.57%	4.91%
Return on Net Nonoperating Assets (RNNOA)	-2.08%	-1.22%	-1.01%
Return on Equity (ROE)	9.23%	9.71%	6.48%
Cash Return on Invested Capital (CROIC)	1.89%	-17.22%	-2.98%
Operating Return on Assets (OROA)	11.83%	10.61%	7.86%
Return on Assets (ROA)	6.87%	7.53%	5.30%
Return on Common Equity (ROCE)	9.16%	9.71%	6.48%
Return on Equity Simple (ROE_SIMPLE)	8.68%	8.99%	6.41%
Net Operating Profit after Tax (NOPAT)	13	10	5.71
NOPAT Margin	5.63%	5.57%	4.11%
Net Nonoperating Expense Percent (NNEP)	-10.27%	0.36%	2.58%
Return On Investment Capital (ROIC_SIMPLE)	9.20%	8.43%	5.88%
Cost of Revenue to Revenue	40.60%	38.37%	39.01%
SG&A Expenses to Revenue	47.36%	48.02%	49.10%
R&D to Revenue	1.37%	1.52%	1.94%
Operating Expenses to Revenue	52.19%	53.85%	55.76%
Earnings before Interest and Taxes (EBIT)	20	14	9.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	45	36	25
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.38	2.65	2.96
Price to Tangible Book Value (P/TBV)	3.20	3.62	2.96
Price to Revenue (P/Rev)	1.39	1.65	2.07
Price to Earnings (P/E)	27.72	29.50	46.20
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	3.61%	3.39%	2.16%
Enterprise Value to Invested Capital (EV/IC)	2.55	2.77	3.37
Enterprise Value to Revenue (EV/Rev)	1.33	1.61	1.95
Enterprise Value to EBITDA (EV/EBITDA)	6.59	8.12	10.88
Enterprise Value to EBIT (EV/EBIT)	15.17	20.43	29.27
Enterprise Value to NOPAT (EV/NOPAT)	23.58	28.89	47.37
Enterprise Value to Operating Cash Flow (EV/OCF)	7.62	6.52	9.75
Enterprise Value to Free Cash Flow (EV/FCFF)	140.85	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.03	0.06	0.00
Long-Term Debt to Equity	0.03	0.05	0.00
Financial Leverage	-0.10	-0.12	-0.21
Leverage Ratio	1.34	1.29	1.22
Compound Leverage Factor	1.11	1.29	1.19
Debt to Total Capital	2.91%	5.85%	0.00%
Short-Term Debt to Total Capital	0.30%	0.89%	0.00%
Long-Term Debt to Total Capital	2.61%	4.96%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.39%	0.00%	0.00%
Common Equity to Total Capital	95.70%	94.15%	100.00%
Debt to EBITDA	0.09	0.19	0.00
Net Debt to EBITDA	-0.36	-0.21	0.00
Long-Term Debt to EBITDA	0.08	0.17	0.00
Debt to NOPAT	0.32	0.69	0.00
Net Debt to NOPAT	-1.29	-0.73	0.00
Long-Term Debt to NOPAT	0.28	0.59	0.00
Altman Z-Score	6.73	6.68	11.14
Noncontrolling Interest Sharing Ratio	0.77%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.42	1.19	2.11
Quick Ratio	1.14	0.97	1.71
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	2.11	-16	-2.27
Operating Cash Flow to CapEx	137.40%	192.19%	126.27%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	1.35	1.35	1.18
Accounts Receivable Turnover	10.34	10.82	9.85
Inventory Turnover	20.35	17.12	17.96
Fixed Asset Turnover	2.99	2.59	0.00
Accounts Payable Turnover	19.17	20.56	18.39
Days Sales Outstanding (DSO)	35.29	33.74	37.07
Days Inventory Outstanding (DIO)	17.93	21.32	20.33
Days Payable Outstanding (DPO)	19.04	17.75	19.85
Cash Conversion Cycle (CCC)	34.18	37.30	37.55
Capital & Investment Metrics	-	-	-
Invested Capital	117	106	80
Invested Capital Turnover	2.01	1.96	1.82
Increase / (Decrease) in Invested Capital	11	26	7.98
Enterprise Value (EV)	298	295	271
Market Capitalization	312	302	287
Book Value per Share	$3.37	$2.96	$2.55
Tangible Book Value per Share	$2.51	$2.17	$2.55
Total Capital	137	121	97
Total Debt	4.00	7.07	0.00
Total Long-Term Debt	3.59	6.00	0.00
Net Debt	-16	-7.45	-17
Capital Expenditures (CapEx)	28	24	22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.58	-5.52	3.97
Debt-free Net Working Capital (DFNWC)	16	7.32	21
Net Working Capital (NWC)	16	6.24	21
Net Nonoperating Expense (NNE)	1.22	-0.04	-0.51
Net Nonoperating Obligations (NNO)	-16	-7.45	-17
Total Depreciation and Amortization (D&A)	26	22	16
Debt-free, Cash-free Net Working Capital to Revenue	-0.70%	-3.02%	2.86%
Debt-free Net Working Capital to Revenue	7.12%	4.00%	15.04%
Net Working Capital to Revenue	6.94%	3.41%	15.04%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.29	$0.27	$0.16
Adjusted Weighted Average Basic Shares Outstanding	38.75M	38.35M	38.66M
Adjusted Diluted Earnings per Share	$0.28	$0.25	$0.16
Adjusted Weighted Average Diluted Shares Outstanding	40.81M	40.38M	39.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.52M	38.76M	38.17M
Normalized Net Operating Profit after Tax (NOPAT)	13	11	5.95
Normalized NOPAT Margin	5.63%	5.82%	4.29%
Pre Tax Income Margin	7.21%	7.86%	6.48%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.32%	0.00%	0.00%
Augmented Payout Ratio	0.32%	0.00%	153.78%

This table displays calculated financial ratios and metrics derived from Viemed Healthcare's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.62%	17.41%	26.91%	27.90%	35.28%	38.15%	30.02%	22.64%	17.35%	22.11%
EBITDA Growth	32.92%	20.94%	15.45%	25.65%	41.42%	81.02%	71.08%	20.05%	1.57%	-2.40%
EBIT Growth	60.46%	39.02%	5.17%	10.67%	48.92%	178.31%	190.01%	-10.36%	-24.24%	-47.72%
NOPAT Growth	24.96%	37.99%	7.63%	14.57%	50.70%	182.38%	216.95%	-7.98%	-36.26%	-37.64%
Net Income Growth	27.24%	33.78%	-36.61%	5.67%	42.62%	176.68%	140.95%	-13.90%	-40.35%	-41.03%
EPS Growth	25.00%	42.86%	-33.33%	0.00%	14.29%	133.33%	200.00%	0.00%	-30.00%	-25.00%
Operating Cash Flow Growth	12.82%	-7.71%	33.57%	-88.81%	72.88%	73.22%	54.12%	46.88%	-11.22%	58.55%
Free Cash Flow Firm Growth	73.56%	85.12%	77.18%	-3,796.13%	-306.01%	-491.90%	-129.38%	110.15%	44.68%	68.13%
Invested Capital Growth	9.88%	7.89%	8.67%	59.38%	32.76%	44.91%	43.89%	0.46%	11.06%	9.05%
Revenue Q/Q Growth	4.64%	5.53%	8.64%	-0.29%	2.71%	14.06%	9.49%	5.46%	4.89%	7.35%
EBITDA Q/Q Growth	20.23%	32.04%	9.95%	-23.85%	9.39%	26.06%	19.65%	-14.29%	40.02%	19.14%
EBIT Q/Q Growth	43.04%	93.38%	36.91%	-57.63%	23.92%	46.30%	44.07%	-42.98%	131.59%	52.45%
NOPAT Q/Q Growth	13.27%	68.00%	42.82%	-54.02%	25.09%	31.03%	52.04%	-39.52%	134.38%	47.07%
Net Income Q/Q Growth	13.29%	164.39%	-7.86%	-53.90%	19.12%	25.28%	53.59%	-37.78%	131.09%	9.10%
EPS Q/Q Growth	0.00%	150.00%	0.00%	-50.00%	14.29%	16.67%	50.00%	-42.86%	133.33%	50.00%
Operating Cash Flow Q/Q Growth	17.59%	25.17%	766.55%	-91.15%	-3.80%	81.15%	-27.37%	36.60%	-3.61%	61.18%
Free Cash Flow Firm Q/Q Growth	-30.76%	35.71%	82.78%	-69.99%	26.42%	1.38%	-2,889.52%	120.06%	-7.26%	61.78%
Invested Capital Q/Q Growth	-0.24%	-1.53%	3.12%	6.78%	-2.04%	-0.82%	51.24%	-9.65%	6.92%	-1.52%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.54%	59.26%	59.84%	58.91%	63.29%	61.86%	60.28%	60.68%	61.04%	60.55%
EBITDA Margin	24.49%	21.31%	17.03%	16.83%	22.04%	20.69%	18.72%	17.13%	21.08%	15.79%
Operating Margin	10.63%	9.70%	6.58%	4.36%	10.42%	8.51%	6.70%	4.89%	9.42%	4.11%
EBIT Margin	13.91%	10.18%	5.55%	4.41%	10.37%	8.60%	6.70%	5.09%	9.42%	4.27%
Profit (Net Income) Margin	7.29%	6.73%	2.69%	3.17%	6.85%	5.91%	5.38%	3.84%	6.50%	2.95%
Tax Burden Percent	70.17%	71.01%	65.79%	75.58%	68.50%	68.86%	76.19%	75.17%	68.02%	69.82%
Interest Burden Percent	74.66%	93.14%	73.53%	95.11%	96.45%	99.81%	105.34%	100.15%	101.41%	99.02%
Effective Tax Rate	29.83%	28.99%	34.21%	24.42%	31.50%	31.14%	23.81%	24.83%	31.98%	30.18%
Return on Invested Capital (ROIC)	14.97%	13.07%	7.79%	6.80%	14.00%	10.84%	8.58%	7.43%	11.68%	5.32%
ROIC Less NNEP Spread (ROIC-NNEP)	15.84%	14.96%	-53.47%	7.24%	15.20%	10.60%	6.59%	7.19%	11.51%	5.17%
Return on Net Nonoperating Assets (RNNOA)	-1.52%	-0.62%	-0.70%	-0.95%	-1.76%	-1.00%	-0.40%	-1.89%	-2.37%	-1.12%
Return on Equity (ROE)	13.45%	12.46%	7.09%	5.85%	12.25%	9.84%	8.18%	5.54%	9.31%	4.20%
Cash Return on Invested Capital (CROIC)	1.89%	2.78%	0.97%	-34.71%	-17.22%	-26.90%	-28.35%	7.26%	-2.98%	1.16%
Operating Return on Assets (OROA)	18.80%	13.68%	7.30%	6.12%	13.96%	10.86%	7.90%	6.11%	11.13%	4.84%
Return on Assets (ROA)	9.85%	9.05%	3.53%	4.40%	9.22%	7.46%	6.34%	4.60%	7.68%	3.35%
Return on Common Equity (ROCE)	13.35%	12.36%	7.03%	5.85%	12.25%	9.84%	8.18%	5.54%	9.31%	4.20%
Return on Equity Simple (ROE_SIMPLE)	0.00%	8.37%	7.94%	8.88%	0.00%	8.46%	7.02%	5.97%	0.00%	8.38%
Net Operating Profit after Tax (NOPAT)	4.53	4.00	2.38	1.67	3.62	2.90	2.21	1.45	2.40	1.03
NOPAT Margin	7.46%	6.89%	4.33%	3.29%	7.14%	5.86%	5.10%	3.68%	6.41%	2.87%
Net Nonoperating Expense Percent (NNEP)	-0.87%	-1.89%	61.26%	-0.44%	-1.20%	0.24%	1.99%	0.25%	0.17%	0.15%
Return On Investment Capital (ROIC_SIMPLE)	3.30%	-	-	-	2.99%	-	-	-	2.48%	-
Cost of Revenue to Revenue	40.46%	40.74%	40.16%	41.09%	36.71%	38.14%	39.72%	39.32%	38.96%	39.45%
SG&A Expenses to Revenue	46.48%	45.98%	48.22%	49.05%	47.11%	47.88%	47.48%	49.96%	45.78%	49.43%
R&D to Revenue	1.32%	1.31%	1.38%	1.48%	1.28%	1.20%	1.75%	1.97%	1.92%	1.87%
Operating Expenses to Revenue	52.19%	50.03%	52.24%	54.60%	52.81%	53.43%	53.58%	56.00%	54.11%	56.60%
Earnings before Interest and Taxes (EBIT)	8.45	5.90	3.05	2.23	5.26	4.25	2.90	2.02	3.53	1.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	15	12	9.36	8.52	11	10	8.11	6.78	7.91	5.65
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.38	2.28	2.13	3.14	2.65	2.38	3.58	3.69	2.96	2.44
Price to Tangible Book Value (P/TBV)	3.20	3.12	2.98	4.25	3.62	3.30	5.05	3.69	2.96	2.44
Price to Revenue (P/Rev)	1.39	1.33	1.24	1.88	1.65	1.52	2.40	2.52	2.07	1.72
Price to Earnings (P/E)	27.72	27.30	26.86	35.38	29.50	27.58	49.14	58.95	46.20	28.71
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.61%	3.66%	3.72%	2.83%	3.39%	3.63%	2.04%	1.70%	2.16%	3.48%
Enterprise Value to Invested Capital (EV/IC)	2.55	2.37	2.14	3.16	2.77	2.38	3.46	4.74	3.37	2.80
Enterprise Value to Revenue (EV/Rev)	1.33	1.30	1.24	1.88	1.61	1.52	2.43	2.35	1.95	1.58
Enterprise Value to EBITDA (EV/EBITDA)	6.59	6.71	6.49	9.59	8.12	7.85	13.41	13.76	10.88	8.84
Enterprise Value to EBIT (EV/EBIT)	15.17	16.88	17.24	24.90	20.43	20.54	38.57	43.23	29.27	22.38
Enterprise Value to NOPAT (EV/NOPAT)	23.58	23.70	24.04	35.05	28.89	28.79	53.44	61.49	47.37	29.74
Enterprise Value to Operating Cash Flow (EV/OCF)	7.62	7.43	6.63	10.16	6.52	6.52	11.23	11.04	9.75	7.31
Enterprise Value to Free Cash Flow (EV/FCFF)	140.85	88.35	230.58	0.00	0.00	0.00	0.00	65.42	0.00	251.78
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.03	0.04	0.08	0.06	0.06	0.09	0.15	0.00	0.00	0.05
Long-Term Debt to Equity	0.03	0.03	0.07	0.05	0.05	0.07	0.12	0.00	0.00	0.04
Financial Leverage	-0.10	-0.04	0.01	-0.13	-0.12	-0.09	-0.06	-0.26	-0.21	-0.22
Leverage Ratio	1.34	1.35	1.39	1.29	1.29	1.33	1.34	1.24	1.22	1.28
Compound Leverage Factor	1.00	1.26	1.02	1.23	1.24	1.32	1.41	1.24	1.24	1.27
Debt to Total Capital	2.91%	3.40%	7.26%	5.30%	5.85%	8.36%	12.76%	0.00%	0.00%	4.40%
Short-Term Debt to Total Capital	0.30%	0.62%	0.59%	0.49%	0.89%	1.54%	2.65%	0.00%	0.00%	0.17%
Long-Term Debt to Total Capital	2.61%	2.78%	6.67%	4.81%	4.96%	6.82%	10.11%	0.00%	0.00%	4.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.39%	1.40%	1.38%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	95.70%	95.20%	91.36%	94.70%	94.15%	91.64%	87.24%	100.00%	100.00%	95.60%
Debt to EBITDA	0.09	0.11	0.24	0.17	0.19	0.30	0.54	0.00	0.00	0.18
Net Debt to EBITDA	-0.36	-0.21	-0.03	-0.02	-0.21	0.00	0.18	0.00	0.00	-0.82
Long-Term Debt to EBITDA	0.08	0.09	0.22	0.16	0.17	0.25	0.43	0.00	0.00	0.17
Debt to NOPAT	0.32	0.38	0.89	0.62	0.69	1.11	2.15	0.00	0.00	0.61
Net Debt to NOPAT	-1.29	-0.74	-0.11	-0.08	-0.73	-0.02	0.71	0.00	0.00	-2.74
Long-Term Debt to NOPAT	0.28	0.31	0.82	0.57	0.59	0.90	1.71	0.00	0.00	0.59
Altman Z-Score	6.52	6.16	5.68	7.77	6.48	5.80	6.87	11.24	10.98	7.58
Noncontrolling Interest Sharing Ratio	0.77%	0.78%	0.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.42	1.31	1.43	1.28	1.19	1.14	1.14	1.99	2.11	2.09
Quick Ratio	1.14	1.10	1.20	1.06	0.97	0.89	0.89	1.79	1.71	1.88
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-5.99	-4.58	-7.12	-41	-23	-31	-31	1.12	-5.58	-5.20
Operating Cash Flow to CapEx	150.65%	256.49%	124.66%	21.90%	177.47%	195.90%	149.88%	268.78%	142.88%	130.62%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.35	1.34	1.31	1.39	1.35	1.26	1.18	1.20	1.18	1.13
Accounts Receivable Turnover	10.34	9.53	9.15	9.51	10.82	10.32	9.70	9.77	9.85	9.63
Inventory Turnover	20.35	18.96	18.05	19.36	17.12	16.87	16.78	19.22	17.96	17.88
Fixed Asset Turnover	2.99	2.90	2.79	2.73	2.59	2.40	0.00	2.21	0.00	2.10
Accounts Payable Turnover	19.17	14.21	12.85	15.00	20.56	13.63	12.46	14.37	18.39	12.24
Days Sales Outstanding (DSO)	35.29	38.30	39.89	38.37	33.74	35.37	37.61	37.36	37.07	37.90
Days Inventory Outstanding (DIO)	17.93	19.25	20.22	18.85	21.32	21.63	21.76	18.99	20.33	20.42
Days Payable Outstanding (DPO)	19.04	25.69	28.40	24.33	17.75	26.78	29.30	25.40	19.85	29.82
Cash Conversion Cycle (CCC)	34.18	31.86	31.71	32.89	37.30	30.23	30.07	30.95	37.55	28.49
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	117	117	119	115	106	109	110	72	80	75
Invested Capital Turnover	2.01	1.90	1.80	2.07	1.96	1.85	1.68	2.02	1.82	1.85
Increase / (Decrease) in Invested Capital	11	8.58	9.50	43	26	34	33	0.34	7.98	6.23
Enterprise Value (EV)	298	278	255	365	295	258	379	343	271	210
Market Capitalization	312	285	254	365	302	258	374	369	287	229
Book Value per Share	$3.37	$3.22	$3.07	$3.00	$2.96	$2.83	$2.73	$2.62	$2.55	$2.46
Tangible Book Value per Share	$2.51	$2.35	$2.20	$2.22	$2.17	$2.04	$1.93	$2.62	$2.55	$2.46
Total Capital	137	131	131	123	121	119	120	100	97	98
Total Debt	4.00	4.46	9.49	6.50	7.07	9.93	15	0.00	0.00	4.32
Total Long-Term Debt	3.59	3.65	8.72	5.91	6.00	8.10	12	0.00	0.00	4.16
Net Debt	-16	-8.68	-1.11	-0.81	-7.45	-0.15	5.06	-26	-17	-19
Capital Expenditures (CapEx)	9.95	4.97	8.17	5.37	7.49	7.05	5.09	3.91	5.38	6.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.58	-1.08	3.67	1.79	-5.52	-3.94	-2.68	-2.25	3.97	-1.23
Debt-free Net Working Capital (DFNWC)	16	12	14	9.10	7.32	6.14	7.54	23	21	22
Net Working Capital (NWC)	16	11	13	8.50	6.24	4.31	4.37	23	21	22
Net Nonoperating Expense (NNE)	0.10	0.09	0.90	0.06	0.15	-0.02	-0.12	-0.06	-0.03	-0.03
Net Nonoperating Obligations (NNO)	-16	-9.55	-2.11	-0.81	-7.45	-0.15	5.06	-28	-17	-19
Total Depreciation and Amortization (D&A)	6.42	6.46	6.31	6.29	5.92	5.98	5.21	4.76	4.37	4.12
Debt-free, Cash-free Net Working Capital to Revenue	-0.70%	-0.50%	1.78%	0.92%	-3.02%	-2.32%	-1.72%	-1.54%	2.86%	-0.92%
Debt-free Net Working Capital to Revenue	7.12%	5.63%	6.94%	4.69%	4.00%	3.62%	4.83%	15.93%	15.04%	16.86%
Net Working Capital to Revenue	6.94%	5.25%	6.56%	4.38%	3.41%	2.54%	2.80%	15.93%	15.04%	16.74%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.11	$0.10	$0.04	$0.04	$0.09	$0.08	$0.06	$0.04	$0.07	$0.03
Adjusted Weighted Average Basic Shares Outstanding	38.75M	38.87M	38.82M	38.72M	38.35M	38.44M	38.32M	38.16M	38.66M	38.23M
Adjusted Diluted Earnings per Share	$0.10	$0.10	$0.04	$0.04	$0.08	$0.07	$0.06	$0.04	$0.07	$0.03
Adjusted Weighted Average Diluted Shares Outstanding	40.81M	40.78M	40.55M	40.58M	40.38M	40.42M	40.68M	40.02M	39.81M	39.58M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.52M	38.94M	38.83M	38.82M	38.76M	38.49M	38.40M	38.28M	38.17M	38.02M
Normalized Net Operating Profit after Tax (NOPAT)	4.53	3.66	2.02	1.83	3.81	3.09	2.30	1.44	2.53	1.23
Normalized NOPAT Margin	7.46%	6.32%	3.68%	3.61%	7.51%	6.25%	5.31%	3.63%	6.73%	3.44%
Pre Tax Income Margin	10.39%	9.48%	4.08%	4.19%	10.00%	8.58%	7.06%	5.10%	9.56%	4.23%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	153.78%	112.54%

Frequently Asked Questions About Viemed Healthcare's Financials

When does Viemed Healthcare's financial year end?

According to the most recent income statement we have on file, Viemed Healthcare's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Viemed Healthcare's net income changed over the last 2 years?

Viemed Healthcare's net income appears to be on an upward trend, with a most recent value of $11.41 million in 2024, rising from $6.22 million in 2022. The previous period was $10.24 million in 2023.

What is Viemed Healthcare's operating income?

Viemed Healthcare's total operating income in 2024 was $17.90 million, based on the following breakdown:

Total Gross Profit: $133.20 million
Total Operating Expenses: $117.04 million

How has Viemed Healthcare revenue changed over the last 2 years?

Over the last 2 years, Viemed Healthcare's total revenue changed from $138.83 million in 2022 to $224.26 million in 2024, a change of 61.5%.

How much debt does Viemed Healthcare have?

Viemed Healthcare's total liabilities were at $43.77 million at the end of 2024, a 6.8% increase from 2023, and a 119.4% increase since 2022.

How much cash does Viemed Healthcare have?

In the past 2 years, Viemed Healthcare's cash and equivalents has ranged from $12.84 million in 2023 to $17.54 million in 2024, and is currently $17.54 million as of their latest financial filing in 2024.

How has Viemed Healthcare's book value per share changed over the last 2 years?

Over the last 2 years, Viemed Healthcare's book value per share changed from 2.55 in 2022 to 3.37 in 2024, a change of 32.1%.

Related Companies

This page (NASDAQ:VMD) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viemed Healthcare (VMD) Financials

Frequently Asked Questions About Viemed Healthcare's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viemed Healthcare (VMD) Financials

Annual Income Statements for Viemed Healthcare

Quarterly Income Statements for Viemed Healthcare

Annual Cash Flow Statements for Viemed Healthcare

Quarterly Cash Flow Statements for Viemed Healthcare

Annual Balance Sheets for Viemed Healthcare

Quarterly Balance Sheets for Viemed Healthcare

Annual Metrics And Ratios for Viemed Healthcare

Quarterly Metrics And Ratios for Viemed Healthcare

Frequently Asked Questions About Viemed Healthcare's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools